Day One Biopharmaceuticals (NASDAQ:DAWN) Given New $43.00 Price Target at The Goldman Sachs Group
Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) had its price objective decreased by The Goldman Sachs Group from $48.00 to $43.00 in a research note released on Monday morning,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock. Several other analysts have also issued reports on DAWN. Needham & Company LLC […]
Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) had its price objective decreased by The Goldman Sachs Group from $48.00 to $43.00 in a research note released on Monday morning,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock. Several other analysts have also issued reports on DAWN. Needham & Company LLC […]
